We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests

By LabMedica International staff writers
Posted on 06 May 2025

Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. More...

While chest X-rays and molecular diagnostics are highly accurate, they are not always accessible in developing nations, where TB rates are high. In these countries, TB is frequently diagnosed by culturing microbes from sputum samples, but this method has a high false negative rate and can be challenging for patients, especially children, to provide a sample. Furthermore, this test requires several weeks for the bacteria to grow, which delays diagnosis. Once the bacteria are in the lungs, their thick cell wall helps them resist the host immune system. This cell wall is largely made up of complex sugar molecules called glycans, but understanding how these glycans defend the bacteria has been difficult. One of the challenges is the lack of an easy method to label these glycans within the cells. Chemists have now overcome this challenge by demonstrating that they can label a specific glycan called ManLAM using an organic molecule that reacts with sulfur-containing sugars. These sugars are found in only three bacterial species, with Mycobacterium tuberculosis, the causative agent of TB, being the most common and problematic.

After successfully labeling the glycan, researchers from the Massachusetts Institute of Technology (MIT, Cambridge, MA, USA) showed that they could track the bacteria as they infected macrophages, immune cells involved in fighting infections. Some researchers studying TB had speculated that the bacterial cells shed ManLAM after entering a host cell and that these free glycans interacted with the host immune system. However, the MIT team discovered that the glycan remains part of the bacterial cell wall for at least the first few days of infection. Moving forward, the researchers plan to use this technique to examine the behavior of the bacteria following antibiotic treatment or immune stimulation of macrophages. This approach could also be useful in studying the assembly of the bacterial cell wall and understanding how ManLAM aids in the bacteria’s entry into macrophages and other cells.

The researchers aim to use this approach to develop a diagnostic method capable of detecting TB-associated glycans, either in cultures or urine samples. Such a test could offer a more affordable and quicker alternative to existing diagnostics. Currently, there is a diagnostic under development that uses antibodies to detect ManLAM in urine samples, but this test is most effective in patients with active TB, particularly those who are immunosuppressed due to HIV or other conditions. By using their small-molecule sensor instead of antibodies, the MIT team hopes to create a more sensitive test that can detect even small amounts of ManLAM in urine samples.

“There aren’t a lot of good diagnostic options, and there are some patient populations, including children, who have a hard time giving samples that can be analyzed. There’s a lot of impetus to develop very simple, fast tests,” said Laura Kiessling, the Novartis Professor of Chemistry at MIT and the senior author of the study.


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
C-Reactive Protein Rapid Test
Afinion CRP
New
Francisella Tularensis Test
TULAREMIA VIRCLIA IgG+IgM MONOTEST
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.